ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 594,15
-0,51%
Dow Jones
40 211,72
0,53%
DAX
18 529,07
-0,38%
Brent Oil
83,675
-0,79%
Bitcoin
63 171,73
-2,59%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
04/12/201015h00Business WireAllos Therapeutics Reports New Analyses of FOLOTYN® Data from PROPEL trial in Relapsed or Refractory Peripheral T-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/12/201015h00Business WireNew Analysis from FOLOTYN® PROPEL Trial Demonstrates Activity in Relapsed or Refractory Transformed Mycosis FungoidesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/12/201014h00Business WireAllos Therapeutics Announces FOLOTYN® Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/11/201014h00Business WireNew FOLOTYN® Data to Be Presented at the 2010 American Society of Hematology Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/201021h10Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/201021h05Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/11/201021h00Business WireAllos Therapeutics Reports Third Quarter 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/10/201022h00Business WireAllos Therapeutics to Report Third Quarter 2010 Financial Results on November 4, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/10/201023h21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/10/201016h06Dow Jones NewsAllos Granted Orphan Status In Europe For Lymphoma DrugNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/10/201015h00Business WireAllos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Hodgkin Lymphoma by the Eu...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/10/201014h19Dow Jones NewsAllos' Pralatrexate Outperforms Tarceva In Lung-Cancer StudyNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/10/201013h15Business WireAllos Therapeutics Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN® in Patients ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/10/201016h00GlobeNewswire Inc.Allos Therapeutics, Inc. (ALTH) to Ring The NASDAQ Stock Market Closing BellNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/09/201022h14Edgar (US Regulatory)Amended Current report filing (8-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/09/201023h40Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/09/201015h00Business WireAllos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/09/201019h29Business WireAllos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO CongressNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/09/201023h50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/201022h19Edgar (US Regulatory)Amended Annual Report (10-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/07/201022h17Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (S-8)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/07/201013h30Business WireAllos Therapeutics Reports Second Quarter 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/07/201013h00Business WireAllos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung CancerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/07/201015h00Business WireAllos Therapeutics to Report Second Quarter 2010 Financial Results on July 28, 2010NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/06/201015h00Business WireAllos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/06/201017h45Business WireAllos Therapeutics’ FOLOTYN Shows Activity & Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refrac...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/06/201015h00Business WireAllos Therapeutics Reports New Data Demonstrating that Responses to FOLOTYN are Correlated with Prolonged Survival in Patient...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/06/201015h00Business WireAllos Therapeutics to Present at Four Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/06/201015h00Business WireAllos Therapeutics Announces FOLOTYN® Data Presentations at the American Society of Clinical Oncology & the Congress of the ...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/05/201015h00Business WireAllos Therapeutics to Present at the Citi Investment Research Global Health Care ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

EU
ML
Michelin
EU
CS
Axa
EU
AF
Air FranceKLM
EU
MC
Lvmh Moet Hennessy Louis...
NYSE
JPM
JP Morgan Chase
SPI
SP500
S&P 500
EU
RNO
Renault
EU
VIV
Vivendi
FTSE
UKX
FTSE 100
EU
GLE
Societe Generale
NYSE
DIS
Walt Disney
NASDAQ
AAPL
Apple
EU
EN
Bouygues
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés